Literature DB >> 24486220

Anti-tumor activity of non-steroidal anti-inflammatory drugs: cyclooxygenase-independent targets.

Jason L Liggett1, Xiaobo Zhang2, Thomas E Eling3, Seung Joon Baek4.   

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are used extensively for analgesic and antipyretic treatments. In addition, NSAIDs reduce the risk and mortality to several cancers. Their mechanisms in anti-tumorigenesis are not fully understood, but both cyclooxygenase (COX)-dependent and -independent pathways play a role. We and others have been interested in elucidating molecular targets of NSAID-induced apoptosis. In this review, we summarize updated literature regarding cellular and molecular targets modulated by NSAIDs. Among those NSAIDs, sulindac sulfide and tolfenamic acid are emphasized in this review because these two drugs have been well investigated for their anti-tumorigenic activity in many different types of cancer.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  COX; NAG-1; NSAIDs; Sulindac sulfide; Tolfenamic acid

Mesh：

Substances：

Year:  2014        PMID： 24486220      PMCID： PMC3965613          DOI： 10.1016/j.canlet.2014.01.021

Source DB:  PubMed          Journal:  Cancer Lett        ISSN： 0304-3835            Impact factor:   8.679


  103 in total

1.  Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities.

Authors:  S J Baek; K S Kim; J B Nixon; L C Wilson; T E Eling
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

2.  Differential activity of sulindac metabolites against squamous cell carcinoma of the head and neck is mediated by p21waf1/cip1 induction and cell cycle inhibition.

Authors:  Jonathan M Bock; Sarita G Menon; Prabhat C Goswami; Lori L Sinclair; Nichole S Bedford; Robert E Jackson; Douglas K Trask
Journal:  Cancer Biol Ther       Date:  2007-01       Impact factor: 4.742

3.  NSAIDs may regulate EGR-1-mediated induction of reactive oxygen species and non-steroidal anti-inflammatory drug-induced gene (NAG)-1 to initiate intrinsic pathway of apoptosis for the chemoprevention of colorectal cancer.

Authors:  Vivek Vaish; Honit Piplani; Chandan Rana; Kim Vaiphei; Sankar Nath Sanyal
Journal:  Mol Cell Biochem       Date:  2013-02-23       Impact factor: 3.396

4.  The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15.

Authors:  Jong-Sik Kim; Seung Joon Baek; Tina Sali; Thomas E Eling
Journal:  Mol Cancer Ther       Date:  2005-03       Impact factor: 6.261

5.  Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.

Authors:  Maen Abdelrahim; Cheryl H Baker; James L Abbruzzese; Stephen Safe
Journal:  J Natl Cancer Inst       Date:  2006-06-21       Impact factor: 13.506

6.  GT-094, a NO-NSAID, inhibits colon cancer cell growth by activation of a reactive oxygen species-microRNA-27a: ZBTB10-specificity protein pathway.

Authors:  Satya S Pathi; Indira Jutooru; Gayathri Chadalapaka; Sandeep Sreevalsan; S Anand; Gregory Rj Thatcher; Stephen Safe
Journal:  Mol Cancer Res       Date:  2010-12-14       Impact factor: 5.852

7.  ESE-1/EGR-1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.

Authors:  Seong-Ho Lee; Jae Hoon Bahn; Chang Kyoung Choi; Nichelle C Whitlock; Anthony E English; Stephen Safe; Seung Joon Baek
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

8.  Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis.

Authors:  F M Giardiello; S R Hamilton; A J Krush; S Piantadosi; L M Hylind; P Celano; S V Booker; C R Robinson; G J Offerhaus
Journal:  N Engl J Med       Date:  1993-05-06       Impact factor: 91.245

9.  NUANCE, a giant protein connecting the nucleus and actin cytoskeleton.

Authors:  Yen-Yi Zhen; Thorsten Libotte; Martina Munck; Angelika A Noegel; Elena Korenbaum
Journal:  J Cell Sci       Date:  2002-08-01       Impact factor: 5.285

10.  Sulindac activates NF-κB signaling in colon cancer cells.

Authors:  Dessislava Mladenova; Laurent Pangon; Nicola Currey; Irvin Ng; Elizabeth A Musgrove; Shane T Grey; Maija R J Kohonen-Corish
Journal:  Cell Commun Signal       Date:  2013-10-01       Impact factor: 5.712
View more
  34 in total

1.  Pilot clinical study of the effects of ginger root extract on eicosanoids in colonic mucosa of subjects at increased risk for colorectal cancer.

Authors:  Suzanna M Zick; D Kim Turgeon; Jianwei Ren; Mack T Ruffin; Benjamin D Wright; Ananda Sen; Zora Djuric; Dean E Brenner
Journal:  Mol Carcinog       Date:  2014-04-24       Impact factor: 4.784

2.  Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.

Authors:  Venkateshwar Madka; Altaf Mohammed; Qian Li; Yuting Zhang; Jagan M R Patlolla; Laura Biddick; Stan Lightfoot; Xue-Ru Wu; Vernon Steele; Levy Kopelovich; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-02

3.  Sinomenine, a COX-2 inhibitor, induces cell cycle arrest and inhibits growth of human colon carcinoma cells in vitro and in vivo.

Authors:  Haibo Yang; Peihao Yin; Zhan Shi; Yanchun Ma; Chenggen Zhao; Jampu Zheng; Teng Chen
Journal:  Oncol Lett       Date:  2015-10-29       Impact factor: 2.967

4.  Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study.

Authors:  Melissa A Merritt; Megan S Rice; Mollie E Barnard; Susan E Hankinson; Ursula A Matulonis; Elizabeth M Poole; Shelley S Tworoger
Journal:  Lancet Oncol       Date:  2018-07-18       Impact factor: 41.316

5.  Diverse amide analogs of sulindac for cancer treatment and prevention.

Authors:  Bini Mathew; Judith V Hobrath; Michele C Connelly; R Kiplin Guy; Robert C Reynolds
Journal:  Bioorg Med Chem Lett       Date:  2017-09-13       Impact factor: 2.823

6.  Combination of clotam and vincristine enhances anti-proliferative effect in medulloblastoma cells.

Authors:  Shruti Patil; Umesh T Sankpal; Myrna Hurtado; W Paul Bowman; Jeffrey Murray; Kathleen Borgmann; Anuja Ghorpade; Robert Sutphin; Don Eslin; Riyaz Basha
Journal:  Gene       Date:  2019-04-13       Impact factor: 3.688

Review 7.  Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again.

Authors:  Ashish Saxena; Daniel Becker; Isabel Preeshagul; Karen Lee; Elena Katz; Benjamin Levy
Journal:  Oncologist       Date:  2015-07-08

8.  Indomethacin can induce cell death in rat gastric parietal cells through alteration of some apoptosis- and autophagy-associated molecules.

Authors:  Sahar M Gebril; Yuko Ito; Masa-Aki Shibata; Kentaro Maemura; Eman E Abu-Dief; Mahmoud R A Hussein; Usama M Abdelaal; Hoda M Elsayed; Yoshinori Otsuki; Kazuhide Higuchi
Journal:  Int J Exp Pathol       Date:  2020-09-28       Impact factor: 1.925

9.  Novel valdecoxib derivatives by ruthenium(ii)-promoted 1,3-dipolar cycloaddition of nitrile oxides with alkynes - synthesis and COX-2 inhibition activity.

Authors:  Silvia Roscales; Nicole Bechmann; Daniel Holger Weiss; Martin Köckerling; Jens Pietzsch; Torsten Kniess
Journal:  Medchemcomm       Date:  2018-02-13       Impact factor: 3.597

10.  Engineering 'Enzymelink' for screening lead compounds to inhibit mPGES-1 while maintaining prostacyclin synthase activity.

Authors:  Diana T Ruan; Nanhong Tang; Hironari Akasaka; Renzhong Lu; Ke-He Ruan
Journal:  Future Med Chem       Date:  2021-06-03       Impact factor: 4.767
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.